Results were recently announced from a Phase 2 trial, launched with support from the Bridge Project, to test a synergistic drug combination identified in the Yaffe lab. Patients with metastatic castration-resistant prostate cancer were assigned one of three different dosing schedules; the majority saw improved or stable disease in all three groups. Additionally, the team has identified a biomarker associated with therapeutic response.